Post-transplant focal segmental glomerulosclerosis (FSGS) is associated with renal allograft loss. Currently, optimal treatment remains controversial.
The aim of our study was to examine the efficacy and safety of therapeutic plasma exchange (TPE), and rituximab (RTX), in the management of post-transplant FSGS. The treatment protocol consisted of RTX and monthly cycles of 5 plasma exchanges for 6 months. We treated 10 transplant recipients with biopsy-proven post-transplant FSGS. Lastly, we compared the studied group to a historic control group of nine patients with post-transplant FSGS.
9 out of 10 patients achieved remission after the conclusion of treatment (4 complete and 5 partial), while 1 patient did not respond to treatment. During the follow-up period, there was one graft loss and one patient died while in remission from unrelated complications. There was a significant reduction in mean uPCR between diagnosis (517.4 ± 524.2 mg/mmol) and last follow-up (87 ± 121.6 mg/mmol) in the patients with sustained remission (p = 0.026). There was no significant decline in eGFR in the eight relapse-free responders at the end of follow-up. (54.4 ± 16.7 from 49.8 ± 20.4 ml/min) (p = 0.6) An increased response rate to the combined TPE and RTX treatment was demonstrated, when compared to a historic control group of nine patients with post-transplant FSGS, as only five out of nine patients achieved remission (two complete and three partial) in that group.
In this study, treatment with TPE and RTX appears to be safe, well tolerated and effective in the management of patients with post-transplant FSGS.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Focal segmental glomerulosclerosis
Urine protein creatinine ratio
Estimated glomerular filtration rate
Foot process effacement
Therapeutic plasma exchange
End-stage renal disease
Human albumin solution
D’Agati VD, et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004;43(2):368–82.
McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414–30.
Genovese G, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329(5993):841–5.
Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant. 2005;5(6):1179–85.
Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant. 2006;6(11):2535–42.
Ponticelli C, Glassock RJ. Posttransplant recurrence of primary glomerulonephritis. Clin J Am Soc Nephrol. 2010;5(12):2363–72.
Chadban S. Glomerulonephritis recurrence in the renal graft. J Am Soc Nephrol. 2001;12(2):394–402.
Francis A, Trnka P, McTaggart SJ. Long-term outcome of kidney transplantation in recipients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2016;11(11):2041–6.
Briganti EM, et al. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med. 2002;347(2):103–9.
Dantal J, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med. 1994;330(1):7–14.
Gungor O, et al. Plasmapheresis therapy in renal transplant patients: five-year experience. Transplant Proc. 2011;43(3):853–7.
Hristea D, et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int. 2007;20(1):102–5.
Rodriguez-Ferrero M, Ampuero J, Anaya F. Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis. Transplant Proc. 2009;41(6):2406–8.
Tsagalis G, et al. Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation. Artif Organs. 2011;35(4):420–5.
Ponticelli C. Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant. 2010;25(1):25–31.
Laufer J, et al. Plasma exchange for recurrent nephrotic syndrome following renal transplantation. Transplantation. 1988;46(4):540–2.
Canaud G, et al. Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: a pilot study. Am J Transplant. 2009;9(5):1081–6.
Gohh RY, et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant. 2005;5(12):2907–12.
Valdivia P, et al. Plasmapheresis for the prophylaxis and treatment of recurrent focal segmental glomerulosclerosis following renal transplant. Transplant Proc. 2005;37(3):1473–4.
Cravedi P, Kopp JB, Remuzzi G. Recent progress in the pathophysiology and treatment of FSGS recurrence. Am J Transplant. 2013;13(2):266–74.
Iharada A, et al. Increased nitric oxide production by T- and B-cells in idiopathic nephrotic syndrome. Pediatr Nephrol. 2009;24(5):1033–8.
Benz K, et al. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol. 2004;19(7):794–7.
Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med. 2006;354(18):1961–3.
Araya CE, Dharnidharka VR. The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review. J Transplant. 2011;2011:374213.
Fornoni A, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3(85):85ra46.
Cameron JS, et al. Focal segmental glomerulosclerosis in fifty-nine renal allografts from a single centre; analysis of risk factors for recurrence. Transplant Proc. 1989;21(1 Pt 2):2117–8.
Garrouste C, et al. Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: clinical outcomes. Transplantation. 2017;101(3):649–56.
Kashgary A, et al. The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: a systematic review and meta-analysis of 77 case-reports and case-series. BMC Nephrol. 2016;17(1):104.
D’Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365(25):2398–411.
Coward RJ, et al. Nephrotic plasma alters slit diaphragm-dependent signaling and translocates nephrin, Podocin, and CD2 associated protein in cultured human podocytes. J Am Soc Nephrol. 2005;16(3):629–37.
Sharma R, et al. Components of normal serum block the focal segmental glomerulosclerosis factor activity in vitro. Kidney Int. 2000;58(5):1973–9.
Wei C, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952–60.
Alachkar N, et al. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation. 2013;96(7):649–56.
Yu H, et al. Rac1 activation in podocytes induces rapid foot process effacement and proteinuria. Mol Cell Biol. 2013;33(23):4755–64.
Alachkar N, Gupta G, Montgomery RA. Angiotensin antibodies and focal segmental glomerulosclerosis. N Engl J Med. 2013;368(10):971–3.
Musante L, et al. Circulating anti-actin and anti-ATP synthase antibodies identify a sub-set of patients with idiopathic nephrotic syndrome. Clin Exp Immunol. 2005;141(3):491–9.
Delville M, et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med. 2014;6(256):256ra136.
Orman SV, et al. Nephrotic syndrome associated with a clonal T-cell leukemia of large granular lymphocytes with cytotoxic function. Arch Intern Med. 1986;146(9):1827–9.
Le Berre L, et al. Induction of T regulatory cells attenuates idiopathic nephrotic syndrome. J Am Soc Nephrol. 2009;20(1):57–67.
Bao L, et al. Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes. Kidney Int. 2002;62(6):2010–21.
Wei C, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol. 2012;23(12):2051–9.
Fujimoto K, et al. Clinical significance of serum and urinary soluble urokinase receptor (suPAR) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese. Clin Exp Nephrol. 2015;19(5):804–14.
Conflict of interest
All the authors have declared no competing interest.
Research involving Human Participants and/or Animals
This article does not contain any studies with human participants or animals performed by any of the authors. This was a retrospective review meeting the criteria for a service evaluation study and hence did not require approval from a Research Ethics Committee. This study was approved by the Departmental Transplant Research Group. This therapeutic protocol for the management of post-transplant FSGS was introduced in our institution in 2011 and became the standard treatment for this clinical condition as approved by the Transplant Clinical and Research Group in our Centre. Our retrospective study is in compliance with the Helsinki Declaration.
All patients gave their consent for treatment and received standard care according to our accepted unit protocol.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Koutroutsos, K., Charif, R., Moran, L. et al. Successful management of post-transplant focal segmental glomerulosclerosis with therapeutic plasma exchange and rituximab. Clin Exp Nephrol 23, 700–709 (2019). https://doi.org/10.1007/s10157-019-01690-0
- Focal segmental glomerulosclerosis
- Therapeutic plasma exchange